Vaughan David Investments’s AstraZeneca AZN Stock Holding History

Vaughan David Investments’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$49.6M	Buy	261,536 +3,703	+1%	+$696K	0.99%	39
2026 Q1	$50.9M	Buy	257,833 +6,074	+2%	+$1.17M	1.08%	40
2025 Q4	$46.3M	Sell	251,759 -3,231	-1%	-$567K	1.01%	43
2025 Q3	$39.1M	Buy	254,990 +2,532	+1%	+$383K	0.84%	60
2025 Q2	$35.3M	Buy	252,458 +6,091	+2%	+$854K	0.79%	68
2025 Q1	$36.2M	Buy	246,367 +7,761	+3%	+$1.12M	0.85%	65
2024 Q4	$31.3M	Buy	238,606 +15,892	+7%	+$2.22M	0.74%	77
2024 Q3	$34.7M	Buy	222,714 +13,991	+7%	+$2.26M	0.8%	74
2024 Q2	$32.6M	Buy	208,723 +18,342	+10%	+$2.76M	0.82%	69
2024 Q1	$25.8M	Buy	+190,381	New	+$25.2M	0.64%	83

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vaughan David Investments's AZN Position: Q2 2026 in Review

Vaughan David Investments increased its AstraZeneca (AZN) stake by 1.4% in Q2 2026, buying an estimated $696K and bringing the position to 261,536 shares worth $49.6M. The position accounts for 0.99% of the portfolio, ranked #39.

Vaughan David Investments first reported a position in AZN in Q1 2024 and has held it in 10 quarters since. The position peaked at $50.9M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Vaughan David Investments held 261,536 shares of AstraZeneca worth $49.6M as of Q2 2026.
Vaughan David Investments bought 3,703 AstraZeneca shares in Q2 2026, an estimated $696K.
AstraZeneca made up 0.99% of Vaughan David Investments's portfolio in Q2 2026, its #39 holding.
Vaughan David Investments first reported a position in AstraZeneca in Q1 2024 and has held it in 10 quarters since.
Vaughan David Investments's AstraZeneca position peaked at $50.9M in Q1 2026.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Vaughan David Investments's 13F filing for Q2 2026, filed 11 Aug 2026.